Tests whether opening blocked heart arteries helps weak hearts
Compares artery-opening procedures with medicine alone in adults with weakened hearts from blocked arteries.
Key facts
- Who runs it
- Samsung Medical Center
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Revascularization Versus Medical Treatment in Patients With Ischemic Left Ventricular Dysfunction
- Status
- Recruiting
- People taking part
- 900 people, planned
- Started
- 16 Jun 2023
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Percutaneous coronary intervention
- Record updated
- 14 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure and a weak heart pump caused by narrowed heart arteries. It compares opening the arteries (PCI) with medicines alone.
- Age
- At least 19 years old.
- Sex
- All sexes can join.
- Disease stage
- Stage C heart failure with left ventricular ejection fraction below 40%. Coronary artery narrowing of more than 50% with proven reduced blood flow to the heart muscle. The narrowing can be treated with PCI.
- Biomarker or test result
- Reduced blood flow to the heart muscle shown by invasive physiologic assessment during a heart artery test.
Main reasons for not taking part
- Heart attack within 4 weeks before randomization
- Heart muscle that is no longer alive on a viability test
- Needing a left ventricular assist device or a heart transplant now
- Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
- Pregnancy or breast feeding
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Subject must be at least 19 years of age
- Patients with stage C heart failure and left ventricular ejection fraction<40%
- Patients with significant coronary artery stenosis (diameter stenosis>50% with proven inducible myocardial ischemia by invasive physiologic assessment)
- Coronary artery disease is amenable for percutaneous coronary intervention (PCI)
- Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive approach and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure
Who cannot take part
- Myocardial infarction by universal definition within 4 weeks of randomization
- Non-viable myocardium in myocardial viability test (cardiac magnetic resonance, dobutamine-stress echocardiography, delayed single-photon emission computerized tomography, or aneurysmal change in echocardiography)
- Patients who need left ventricular assisted device (LVAD) or heart transplantation at the time of randomization
- Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
- Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may result in protocol non-compliance (per site investigator's medical judgment)
- Target lesions not amenable for PCI by operators' decision
- Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
- Pregnancy or breast feeding
- Unwillingness or inability to comply with the procedures described in this protocol
Where in South Korea
- Samsune Medical CenterSeoul, South KoreaContact: Young Bin Song, MD, PhDTaking people
About the trial
What the trial wants to find out
Randomized trial to compare clinical outcomes between revascularization versus medical treatment alone in patients with ischemic cardiomyopathy and left ventricular dysfunction.
The 2 groups in the trial
- Guideline-directed medical treatment groupNo study treatment, for comparison
In the GDMT group, medical treatment for patients with left ventricular dysfunction will be performed under current ACC/AHA/SCAI or ESC/EACTS guidelines for heart failure.
- Revascularization groupTreatment being tested
In the revascularization group, patients will undergo percutaneous coronary intervention (PCI) using standard techniques under current ACC/AHA/SCAI or ESC/EACTS guidelines. In the revascularization group, the procedure must be within 2 weeks of randomization. Revascularization criteria is presented as below. Revascularization indication 1. Diameter stenosis \>90% by visual assessment 2. Functionally significant stenosis (FFR≤0.80 or non-hyperemic pressure ratios≤0.89) 3. Chronic total occlusion with substantial ischemic territory. The below locations will be judged as having substantial ischemic territory. * Left main artery * Proximal to mid left anterior descending artery * Proximal left circumflex artery in left dominant coronary arterial system * Proximal to distal right coronary artery in right dominant coronary arterial system
Treatment: Percutaneous coronary intervention
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Trial of Revascularization Versus Medical Treatment on Clinical Outcomes in Patients With Reduced Left Ventricular Function
- Plain-language title
- Tests whether opening blocked heart arteries helps weak heartsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 March 2025